Abstract. Traumatic brain injury (TBI) is a major public health problem and a major cause of mortality and disability that imposes a substantial economic burden worldwide. Dexmedetomidine (DEX), a highly selective α-2-adrenergic receptor agonist that functions as a sedative and analgesic with minimal respiratory depression, has been reported to alleviate early brain injury (EBI) following traumatic brain injury by reducing reactive oxygen species (ROS) production, apoptosis and autophagy. Autophagy is a programmed cell death mechanism that serves a vital role in neuronal cell death following TBI. However, the precise role of autophagy in DEX-mediated neuroprotection following TBI has not been confirmed. The present study aimed to investigate the neuroprotective effects and potential molecular mechanisms of DEX in TBI-induced EBI by regulating neural autophagy in a C57BL/6 mouse model. Mortality, the neurological score, brain water content, neuroinflammatory cytokine levels, ROS production, malondialdehyde levels and neuronal death were evaluated by TUNEL staining, Evans blue extravasation, ELISA, analysis of ROS/lipid peroxidation and western blotting. The results showed that DEX treatment markedly increased the survival rate and neurological score, increased neuron survival, decreased the expression of the LC3, Beclin-1 and NF-κB proteins, as well as the cytokines IL-1β, IL-6 and TNF-α, which indicated that DEX-mediated inhibition of autophagy and neuroinflammation ameliorated neuronal death following TBI. The neuroprotective capacity of DEX is partly dependent on the ROS/nuclear factor erythroid 2-related factor 2 signaling pathway. Taken together, the results of the present study indicated that DEX improves neurological outcomes in mice and reduces neuronal death by protecting against neural autophagy and neuroinflammation.

Introduction

Traumatic brain injury (TBI) is a major public health problem and a major cause of mortality and disability that imposes a substantial economic burden worldwide. A previous study reported that there were ~288,000 TBI-related hospitalizations and >56,000 TBI-related deaths in the US alone, and the global economic burden of TBI was estimated at ~$400 billion per annum (1,2). TBI has a high incidence in low-income and middle-income countries, as well as developing countries such as Iran and China (3-5). The incidence of TBI is increasing rapidly due to the significant increase in road traffic collisions, including motor vehicle accidents (5). Although an increasing number of randomized controlled trials including intracranial pressure monitoring, therapeutic hypothermia, surgical methods and drug administration have been performed in recent years and the long-term outcome has substantially improved, a significant benefit is not observed following drug interventions (4-10). Hence, studies aiming to further clarify the pathophysiological mechanisms of TBI and search for new and effective pharmacological intervention targets are important and necessary. The pathophysiology of TBI includes several different physiological changes and mainly involves primary brain injury and secondary brain injury, which lead to neuronal death, neurological deficits and mortality following TBI (11). Primary brain injuries lead to brain tissue disorganization, intracerebral hemorrhage and blood-brain barrier (BBB) damage, which is a direct physical injury to brain tissue that is difficult to prevent and usually cannot be reversed. Secondary brain injury, including calcium overload, oxidative stress, neuroinflammation, autophagy, lipid peroxidation and apoptosis, can be reversed (12,13).

Autophagy is the main cellular lysosomal degradation mechanism for degrading and recycling intracellular proteins and organelles under different physiological and pathological conditions. It is a self-digestion process that is important for cellular homeostasis and survival, and is involved in many human diseases including neurodegenerative disorders and cancer (14). In TBI, autophagy is activated to protect neurons, but an excessive autophagy can lead to cell death (15). Therefore, it is of great significance to investigate the role of autophagy in TBI and develop effective strategies to regulate autophagy in the treatment of TBI.

Dexmedetomidine alleviates early brain injury following traumatic brain injury by inhibiting autophagy and neuroinflammation through the ROS/Nrf2 signaling pathway

XIAOYAN FENG1*, WEIWEI MA2*, JIE ZHU1, WEI JIAO1 and YUHAI WANG1

1Department of Neurosurgery, Wuxi Clinical College of Anhui Medical University, 904th Hospital of Joint Logistic Support Force of PLA, Wuxi, Jiangsu 214044; 2Clinical Medicine Five-Year Program, 11 Class, 2019 Grade, Wannan Medical College, Wuhu, Jiangsu 241002, P.R. China

Received April 22, 2021; Accepted June 29, 2021

DOI: 10.3892/mmr.2021.12300

Correspondence to: Dr Yuhai Wang, Department of Neurosurgery, Wuxi Clinical College of Anhui Medical University, 904th Hospital of Joint Logistic Support Force of PLA, 101 Xing Yuan North Road, Wuxi, Jiangsu 214044, P.R. China
E-mail: wangyuhai1516@163.com

*Contributed equally

Key words: dexmedetomidine, traumatic brain injury, early brain injury, autophagy, neuroinflammation
conditions (14). Autophagy has been reported to have a core role in many central nervous system diseases, including acute brain injury (12,15,16), intracerebral hemorrhage (17), subarachnoid hemorrhage (SAH) (18) and Huntington’s disease (19). Tang et al (15) reported significant decreases in neural apoptosis and necrotic cell death following autophagy was inhibited by fibroblast growth factor-2 and the autophagy activator rapamycin aggravated brain injury. According to Fang et al (16), activation of autophagy decreases mitochondrial apoptosis, improves neurological function, decreases cerebral edema and alleviates the disruption of the BBB following TBI in mice. Currently, the neuroprotective effect of the activation or inhibition of autophagy remains to be elucidated. A further study of new potential drug targets in the autophagy pathway is required.

Dexmedetomidine (DEX) is a highly selective α2-adrenergic receptor agonist that provides sedation and analgesic effects with minimal respiratory depression (20). It is widely used in surgical procedures and to prevent postoperative delirium (12,21). Recent studies have confirmed that DEX exerts its protective effects on various organ injuries (12,20). Based on accumulating evidence, DEX also improves neurological function and delirium in patients (21) and alleviates EBI in the TBI model and the effect of DEX is dose-dependent (12,22,23). Huang and Hao (22) report that DEX relieves early brain injury (EBI) by inhibiting inflammation and decreasing neuronal apoptosis, which may depend on the TLR4/NF-κB signaling pathway. Li et al (24) also report that DEX alleviates EBI by inhibiting inflammation through the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway. As shown in the study by Zhao et al (25), DEX increases autophagy, decreases reactive oxygen species (ROS) production and apoptosis and then eliminates damaged mitochondria in a lipopolysaccharide-induced acute kidney injury model through the PI3K/AKT/mTOR pathway. The AKT/mTOR signaling pathway is generally acknowledged as the most important regulatory pathway in autophagy (26,27). ROS regulate the NFE2L2 (nuclear factor, erythroid derived 2, like 2) pathway, transcriptionally activates hypoxia-inducible factor (HIF-1) and p53 and then promotes autophagy (28,29). Our previous studies revealed an important role for Nrf2 in neuronal death in diseases of the central nervous system (30,31). However, researchers have not determined whether DEX attenuates EBI by regulating autophagy via the ROS/Nrf2 signaling pathway.

The present study constructed a mouse TBI model to study the effects of DEX on EBI and explored the crosstalk between autophagy and inflammation. It also explored the mechanism by which the ROS/Nrf2 signaling pathway may regulate this process.

Materials and methods

Animals. All animal experiments performed in this study complied with the National Institutes of Health guidelines for the handling of laboratory animals (32) and were approved by the Ethics Committee of the Wuxi Medical College of Anhui Medical University (approval no. YXLL-2020-112). All experiments were conducted on healthy adult male C57BL/6J mice (age, 8-10 weeks; weight, 22-25 g; Anhui Medical University, Hefei, China). The mice were housed in animal care facilities under environmentally controlled temperature (25±2°C) and humidity (55±5%) with 12-h light/dark cycles, and had free access to food and water. The 60 mice were divided into four major groups (15 animals/group): Sham, TBI, TBI + DEX and TBI + DEX + Rap.

Animal TBI model. The TBI model was established in strict accordance with the Feeney weight-drop model of focal injury (33,34). Briefly, the mice were anesthetized with an intraperitoneal injection of 1% sodium pentobarbital (40 mg/kg) and then placed in a brain stereotaxic apparatus. The rectal temperature was maintained at 37±0.5°C during the operation using a heating pad. Then, a burr hole was made in the left hemisphere at the following coordinates: 0.2 mm posterior, 1 mm lateral and 2.2 mm below the horizontal plane of the bregma. The bone flap was removed to expose the dura mater. The dura was placed under a weight-drop device with an impact sensor. A metal (weight 240 g, tip diameter 3 mm) was dropped from 1 cm above the dura onto the dura mater through a catheter. Then, the scalp was closed and the mice were removed from the apparatus. Finally, the hole was covered with medical bone wax. The animals in the Sham group received similar surgical procedures but without weight-drop impact. At 72 h following TBI, the mice were sacrificed with 100 mg/kg sodium pentobarbital via i.p. injection. Mortality was confirmed by observing respiration and by using the corneal reflection method.

Drug administration. DEX was purchased from Jiangsu Hengrui Medicine Co., Ltd., dissolved in 0.9% sterile saline and administered i.p. at a dose of 20 µg/kg 2 h after recovery (12) (Fig. 1A). A dose of 2 mg/kg rapamycin (Selleck Chemicals; dissolved in 2% DMSO) was administered i.p. 30 min before TBI induction in the TBI + rapamycin + DEX group.

Modified neurological severity score (mNSS). The severity of brain injury was evaluated by determining neurological function 72 h after TBI using a previously described neurological grading system (15). The neurological scores of the animals in each group were evaluated by an independent observer. The scoring system consisted of motor, sensory, reflex and balance tests. The neurological scores (mNSS scores) ranged from 0 to 18 points and were calculated by adding the scores together; all mice in each group underwent a behavioral assessment and a higher score represented worse neurological function. All mouse behavior scores were recorded by the same independent observer who was blinded to the study groups.

Brain water content measurement. The severity of brain edema was evaluated by measuring the brain water content using the standard wet-dry method, as previously reported (18,31,35). The mice were sacrificed 72 h after TBI and the entire brain was harvested and separated into the ipsilateral and contralateral cortices, ipsilateral and contralateral basal ganglia and cerebellum (wet weight). Then, brain specimens from each group were dehydrated at 105°C for 24 h to acquire the dry weight. The percentage of brain water content was equal to (wet weight-dry weight)/wet weight x100%.

Evans blue extravasation. Evans blue extravasation was performed as previously described (36). Briefly, mice were
anesthetized by 1% sodium pentobarbital (50 mg/kg) injection 72 h after TBI. Evans blue dye (2%, 5 ml/kg; Sigma-Aldrich; Merck KGaA) was injected into the left femoral vein over 2 min and circulated for 60 min. Then, the mice were sacrificed with 100 mg/kg sodium pentobarbital via i.p. injection and with phosphate-buffered saline (PBS) intracardiac perfusion. Mortality was identified by observing respiration and by using the corneal reflection method. The brains were removed and quickly divided into the left and right cerebral hemispheres, weighed, homogenized in saline and centrifuged at 15,000 x g for 30 min at room temperature. Subsequently, the resultant supernatant was added with an equal volume of trichloroacetic acid, incubated overnight at 4°C and centrifuged at 15,000 x g for 30 min at room temperature. Next, the resultant supernatant was collected and spectrophotometrically quantified at 610 nm for Evans blue dye.

Cytokine measurements. IL-1β (cat. no. ab197742; Abcam), IL-6 (cat. no. ab222503; Abcam), TNF-α (cat. no. ab208348; Abcam) and NF-κB (cat. no. ab176663; Abcam) levels were measured using ELISAs according to the manufacturer’s instructions.

Analysis of ROS. The nonfluorescent diacetylated 2’,7’-dichlorofluorescein (DCF-DA) probe (Sigma-Aldrich; Merck KGaA), which becomes highly fluorescent upon oxidation, was used to evaluate intracellular ROS production according to the manufacturer’s instructions.

Analysis of lipid peroxidation. Malondialdehyde (37) levels were detected with a lipid peroxidation (37) assay kit (Ex/Em 532/553 nm, cat. no. ab118970; Abcam) according to the manufacturer’s instructions.

TdT-mediated dUTP-biotin nick end labeling (TUNEL) assay. A TUNEL assay was conducted to assess neuronal death in the hippocampus. The TUNEL reaction mixture (50 µl) was added to each sample and the slides were incubated in a humidified chamber for 60 min at 37°C in the dark. The slides were then incubated with DAPI (0.1 mg/ml) for 5 min at room temperature in the dark to stain the nuclei, followed by imaging with a fluorescence microscope. The procedure was performed with a TUNEL staining kit according to the manufacturer’s instructions (cat. no. TUN11684817, Roche Diagnostics GmbH). A negative control (without the TUNEL reaction mixture) was used. The apoptotic index (%) was calculated as the ratio of the number of TUNEL-positive cells/total number of cells x100. The cell count was confirmed in four randomly selected high-power fields and the data obtained from each field were averaged (magnification, x400).

Western blot analysis. Western blot analyses were performed as previously described (18). Briefly, cerebral cortex samples were collected, homogenized and total protein was extracted using RIPA buffer (CoWin Biosciences). A BCA Protein Assay kit (Beyotime Institute of Biotechnology) was used to measure protein concentrations with the bicinchoninic acid method. Total protein (30 µg) was separated via 12% SDS-PAGE and transferred onto PVDF membranes. The membranes were blocked with 5% nonfat milk at room temperature for 1 h. The membranes were then incubated with the following primary antibodies overnight at 4°C: Rabbit anti-β-actin (1:1,000; rabbit polyclonal; cat. no. ab2227; rabbit anti-caspase-3 (1:2,000; rabbit polyclonal; cat. no. ab184787; rabbit anti-Nrf2 (1:1,000; rabbit polyclonal; cat. no. ab31163), rabbit anti-heme oxygenase (HO)-1 (1:1,000; rabbit polyclonal; cat. no. ab13243), rabbit anti-Beclin-1 (1 µg/ml, rabbit monoclonal; cat. no. ab62557) and rabbit anti-LC-3B (1 µg/ml, rabbit monoclonal; cat. no. ab48394; all from Abcam). After washing the membranes with TBST (0.5% Tween-20) three times at room temperature for 20 min, HRP-conjugated goat anti-rabbit IgG or goat anti-mouse IgG secondary antibodies (1:2,000; cat. no. 7074s; Cell Signaling Technology, Inc.) were applied and the membranes were incubated with the secondary antibodies at room temperature for 1.5 h. The protein bands were detected using a Bio-Rad imaging system (Bio-Rad Laboratories, Inc.) and quantified with ImageJ software (version 1.52; National Institutes of Health).

Statistical analysis. The data are reported as the means ± standard error of mean. SPSS v14.0 (SPSS, Inc.) and GraphPad Prism 6 (GraphPad Software, Inc.) software were used for the statistical analyses. Student's t-test (unpaired) was used if two independent variables were compared and one-way analysis of variance (ANOVA) followed by Bonferroni’s post hoc test was used if two independent variables were compared. For nonnormally distributed data and/or data with a nonhomogeneous variance, the Kruskal-Wallis test followed by Dunn’s post hoc test was used. P<0.05 was considered to indicate a statistically significant difference.

Results

DEX alleviates neurological deficits and brain edema following TBI. The modified neurological severity score (mNSS) was calculated to evaluate neurological deficits and the brain water content determined using the wet-dry method at 72 h after
TBI to evaluate brain damage and clarify the neuroprotective effect of DEX on TBI. TBI significantly increased the neurological scores and DEX administration significantly improved neurological function (Fig. 1B). Similar results were obtained for brain water content, which were increased significantly after TBI and was alleviated by DEX treatment (P<0.05; Fig. 1C).

**DEX alleviates neuronal apoptosis and BBB permeability following TBI.** Neuronal apoptosis and BBB permeability are the main factors that lead to EBI following TBI. Therefore, a TUNEL assay was used to evaluate the level of cell death in TBI mice treated with and without DEX at 72 h after model construction. The expression levels of apoptosis-related proteins were detected using Western blotting. The results revealed more hippocampal neuronal death following TBI and DEX decreased neuronal apoptosis (Fig. 2A). The western blot results also indicated that DEX reduced the expression levels of the apoptosis-related protein caspase-3 (Fig. 2B-D). Compared with the sham and TBI groups, DEX
Figure 3. DEX alleviates neuroinflammation following TBI. DEX significantly reduced hippocampal (A) TNF-α, (B) IL-1β, (C) IL-6 and (D) NF-κB levels at 72 h after TBI (n=5, P<0.05, ANOVA; means ± standard error of mean). DEX, dexmedetomidine; TBI, traumatic brain injury.

Figure 4. DEX inhibits TBI-induced autophagy activation in the hippocampus. (A) The expression of LC3 and Beclin-1 in the brain cortex of mice with TBI was determined using western blotting. (B) Quantification of LC3 and Beclin-1 levels in the brain cortex relative to β-actin, the loading control. DEX reduced LC3 and Beclin-1 expression in mice with TBI (n=5, P<0.01; ANOVA; means ± standard error of mean). (C) Representative pictures of double staining for LC3 and NeuN in the injured hippocampus following TBI. LC3-positive neurons were rarely observed in the hippocampus of the sham group and DEX decreased the number of LC3-positive neurons. Scale bar=20 μm (magnification, x400). DEX, dexmedetomidine; TBI, traumatic brain injury.
DEX alleviates neuroinflammation following TBI. As previous studies have identified a vital role for neuroinflammation in EBI following TBI, increased neuroinflammation significantly decreased the extent of damage to the blood-brain barrier (Fig. 2E). Based on these results, DEX exerted neuroprotective effects following TBI.

Figure 5. Rap stimulates autophagy and reverses the neuroprotective effect of DEX. Pretreatment with rapamycin significantly increased the (A) mNSS, (B) The brain water content and (C) BBB permeability compared with the TBI + DEX group (n=10, P<0.05). (D) Rapamycin increased neuronal apoptosis in the injured hippocampus compared with the TBI + DEX group (magnification, x400). (E) Levels of LC3, Beclin-1 and caspase-3 in the brain cortex of mice with TBI were determined using western blotting. (F) Quantification of LC3, Beclin-1 and caspase-3 levels in the brain cortex relative to β-actin, the loading control. Rap increases the LC3, Beclin-1 and caspase-3 levels in DEX-treated mice following TBI (n=5, ANOVA; means ± standard error of mean). Rap, rapamycin; DEX, dexmedetomidine; mNSS, modified neurological severity score; TBI, traumatic brain injury; BBB, blood-brain barrier; DAPI, 4′,6-diamidino-2-phenylindole.
aggravates EBI (12,20,22,24). The inflammatory complex induces the secretion of pro-inflammatory cytokines, including IL-1β, IL-6 and TNF-α and the subsequent activation of pro-inflammatory signaling through NF-κB to initiate pyroptosis. Therefore, the hippocampal levels of IL-1β, IL-6, TNF-α and NF-κB were measured using ELISAs. The levels of the pro-inflammatory cytokines were increased significantly following TBI, while their levels decreased significantly following DEX treatment (Fig. 3A-D). Hence, these results suggested that DEX exhibited potent anti-inflammatory activity against TBI-induced neuroinflammation.

**DEX inhibits TBI-induced autophagy activation in the hippocampus.** To clarify whether autophagy serves an important role in TBI and the regulatory effect of DEX

---

Figure 6. DEX regulates autophagy following TBI by modulating the ROS/Nrf2 signaling pathway. A-B: The levels of (A) ROS and (B) MDA were increased following TBI and decreased significantly following DEX treatment. (C) The expression of Nrf2 and HO-1 in the brain cortex of mice with TBI was determined using western blotting. Quantification of (D) Nrf2 and (E) HO-1 levels in the brain cortex relative to the β-actin loading control. DEX increased Nrf2 and HO-1 expression in mice with TBI (n=5, P<0.01; ANOVA; mean ± SEM). DEX, dexmedetomidine; TBI, traumatic brain injury; ROS, reactive oxygen species; Nrf2, nuclear factor erythroid 2-related factor 2; MDA, malondialdehyde; HO, heme oxygenase.
on autophagy, the levels of the autophagy-related proteins Beclin-1 and LC3 in each group were detected using western blotting (Fig. 4A). The levels of both Beclin-1 and LC3 were increased following TBI but decreased significantly following DEX treatment (Fig. 4B). LC3 is a biomarker for autophagy activation and LC3 was chosen to mark autophagic cells. Immunofluorescence staining showed few LC3-positive neurons in the hippocampus of the Sham group, but were widespread in the hippocampus following TBI induction. However, the number of LC3-positive neurons decreased following DEX administration (Fig. 4C).

**Rapamycin stimulates autophagy and reverses the neuroprotective effect of DEX.** Rapamycin is a specific activator of autophagy (18). Mice were pretreated with rapamycin before the induction of TBI to investigate the relationship between autophagy and the neuroprotective effect of DEX. Pretreatment with rapamycin dramatically enhanced neurological deficits (Fig 5A), aggravated brain edema (Fig 5B) and BBB permeability (Fig 5C) and reversed the neuroprotective effect of DEX. Additionally, the TUNEL assay also showed that rapamycin also significantly increased neuronal apoptosis in the injured hippocampus compared with the TBI + DEX group (Fig 5D). Levels of autophagy-related proteins and apoptosis-related proteins were detected using western blotting (Fig. 5E). DEX significantly decreased the levels of caspase 3, Beclin-1 and LC3 (Fig. 5F) but these changes were partially blocked by rapamycin administration. Thus, rapamycin activated autophagy, abolished the anti-autophagy effects of DEX and reversed the neuroprotective effects of DEX on TBI.

**DEX regulates autophagy by modulating the ROS/Nrf2 signaling pathway following TBI.** AKT/mTOR is a core signaling pathway of cell autophagy. According to previous studies, activation of the AKT/mTOR signaling pathway is partially dependent on ROS production (38,39). The present study explored whether autophagy inhibition by ROS occurred through the ROS/Nrf2 signaling pathway following DEX treatment. ROS levels were detected with a DCF-DA probe and the degree of membrane lipid peroxidation evaluated by measuring the MDA content. The levels of ROS and MDA were significantly increased following TBI but decreased following DEX treatment (Fig. 6A and B). The levels of the Nrf2 and HO-1 protein were detected by performing western blotting to investigate neuronal autophagy (Fig. 6C). The levels of Nrf2 and HO-1 were decreased significantly in the TBI group and increased following DEX administration (Fig. 6D and E). Thus, these results showed that DEX may inhibit TBI-induced autophagy by regulating the ROS/Nrf2 signaling pathway.

**Discussion**

The present study evaluated the therapeutic potential of DEX to alleviate EBI in a mouse model of TBI. It was demonstrated that DEX is a neuroprotective agent that attenuated EBI following TBI. It was found that DEX i) improved neurological dysfunction following TBI, ii) alleviated brain damage in a mouse TBI model, iii) relieved neuroinflammation following TBI and then decreased inflammatory damage in the brain and iv) prevented autophagy following TBI and alleviated neuronal death, and v) the anti-neuroinflammatory and anti-autophagy effects of DEX may be related to the ROS/Nrf2 pathway (Fig. 7).
The present study, to avoid bias of biological sex and gonadal hormone status, used healthy adult male C57BL/6J mice not females. The main reason was that studies indicate that biological sex and sex hormone levels may affect the outcome following TBI (40,41). A recent study also recommends that studies should include information on gonadal hormone status and need to include biological sex and gonadal hormone status in the design and analysis following TBI (42).

DEX, a highly selective α-2-adrenergic receptor agonist with anxiolytic, sedative and analgesic properties, has been widely used as an adjuvant during general anesthesia and anti-delirium with minimal respiratory depression (12,21). Clinical studies have shown that the administration of low-dose DEX to critically ill adults reduces the incidence of delirium during stays in intensive care units and reduces cognitive decline for up to one postoperative month in elderly patients undergoing scheduled laparotomy (21,43,44), but the specific neuroprotective mechanism remains to be elucidated. Chen et al (45) aimed to further clarify the mechanisms and report that DEX protects against MTX-induced cognitive impairment by inhibiting neuronal toxicity and inflammation. In hypoxia-activated BV2 microglia and neonatal rats subjected to hypoxia, DEX decreases hippocampal synaptic loss and neuronal damage and the potential mechanisms may be that DEX prevents hypoxia-induced microglial NOX2 activation and then inhibits oxidative stress and the neuroinflammatory response (46). Mei et al (47) also report that DEX alleviates BBB disruption, learning and memory impairments, systemic inflammation and neuroinflammation in a cecal ligation and puncture (CLP)-induced septic model. Hence, the anti-inflammatory and anti-neuroinflammation effects serve an important role in neuroprotection following DEX treatment. As shown in the present study, DEX alleviated neuroinflammation in mouse TBI models. Additionally, DEX directly regulates several cell death models (22,25,48-51). According to Gao et al (49), DEX induces the expression of the neuroglobin protein in hippocampal tissues and then inhibits neuronal apoptosis through the mitochondrial pathway. Sun et al (50) indicate that DEX may preserve brain function and ultimately improve the outcome of sepsis by decreasing pyroptosis and subsequently protecting neurons. In Shen et al (51), DEX postconditioning also improves cardiac outcomes and neurological function following cardiac arrest and resuscitation in swine, partly by suppressing cell necroptosis. Zhao et al (25) report that DEX alleviates acute kidney injury by increasing autophagy through the modulation of the PI3K/AKT/mTOR pathway. At present, the neuroprotective effect of DEX-regulated autophagy activation or inhibition remains to be elucidated.

Autophagy regulates the turnover of cellular constituents to ensure the removal and recycling of toxins and is important in cell homeostasis (52). The role of autophagy has been confirmed in many central nervous system diseases, including acute brain injury (12,15,16), intracerebral hemorrhage (17), SAH (18) and Huntington's disease (19). Autophagy transports materials in cells to lysosomes for degradation through different pathways involved in the regulation of cell survival and death mechanisms following TBI (53). Therefore, autophagy serves a very important role in neuronal injury and repair following TBI. Xue et al (54) report that DEX improves long-term learning cognitive function by inhibiting neuronal autophagy in a neonatal rat model of hypoxic-ischemic brain injury. As shown in Li et al (12), DEX reverses upregulated circLrp1b and Dram2 expression and downregulates miR-27a-3p expression to subsequently inhibit excessive autophagy and improve the TBI-induced neurological impairment. Based on the findings reported by Zhao et al (25), DEX promotes cell autophagy and subsequent LPS-induced acute kidney injury. Yang et al (20) also report that the protective effect of DEX is based on the activation of autophagy through the α2-adrenoceptor/AMPK/mTOR pathway. In the present study, autophagy was excessively activated following TBI and then led to neurological impairments, BBB disruption, brain edema and neuronal apoptosis, which were reversed by the DEX treatment.

The mechanisms and molecules regulating the autophagy pathway are complex and involve mTOR-dependent and non-dependent pathways. The upstream regulatory pathway of mTOR includes AMPK and the PI3K/AKT pathway (13,20). As shown in the present study, DEX decreased levels of ROS production, subsequently inhibiting the activation of autophagy. In the nucleus, ROS regulate the Nrf2 pathway, transcriptionally activate hypoxia-inducible factor (HIF-1) and p53 and then promote autophagy (28,29). Wang et al (55) report that rehmapicrogenin improves adriamycin-induced nephropathy in vivo and in vitro and the mechanisms may be to reduce ROS accumulation and then alter the expression levels of Nrf2. Nrf2 regulates the expression of >250 genes through a specific binding site. The majority of these genes regulate oxidative stress and cell apoptosis, autophagy and ferroptosis (30). TBI leads to intracellular ROS accumulation and decreases the expression levels of Nrf2 and HO-1 and the Nrf2/HO-1 signaling pathway also directly regulates autophagy (56). In the present study, DEX decreased ROS levels and then downregulated Nrf2 and HO-1 expression in the experimental TBI model. DEX ameliorated EBI following TBI by inhibiting neuroinflammation and autophagy via the Nrf2/HO-1 pathway. The specific mechanism remains unclear and other potential molecular mechanisms may serve important roles. Therefore, further research is needed to explore these mechanisms. In addition, the experiments was performed in mice and debate persists regarding whether the treatment is effective in humans. In the future, the clinical effect of DEX will be explored on patients with TBI.

In summary, the present study provided evidence that autophagy, which is mediated by ROS and Nrf2, was an important cellular regulatory mechanism and contributed to EBI following TBI. The present study reported the DEX-mediated regulation of autophagy by the ROS/Nrf2 pathway and provided a new way to explore the biological effects and mechanisms underlying the anti-autophagy, anti-inflammatory and neuroprotective properties of DEX.

Acknowledgements

Not applicable.

Funding

The present study was supported by the National Natural Science Foundation of China (grant no. 81871589) and the Wuxi Municipal Bureau on Science and Technology (grant no. N20201008).
Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

XF and WM performed the experiments and wrote the manuscript. XF, JZ, WJ and YW assisted in performing the experiments and prepared all the figures. YW and WM designed the study and revised the manuscript. XF, YW and WM confirm the authenticity of all the raw data All authors read and approved the final manuscript.

Ethics approval and consent to participate

All animal experiments performed in this study complied with the National Institutes of Health guidelines for the handling of laboratory animals and were approved by the Ethics Committee of the Wuxi Medical College of Anhui Medical University (approval no. YXLL-2020-112).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Rowell SE, Meier EN, McKnight B, Kannadas D, May S, Sheehan K, Bulger EM, Idris AH, Christenson J, Morrison LI, et al. Effect of out-of-Hospital tranexamic acid vs placebo on 6-month functional neurologic outcomes in patients with moderate or severe traumatic brain injury. JAMA 324: 961-974, 2020.

2. Shankar J and Vandorpe R: CT perfusion for confirmation of brain death. AJNR Am J Neuroradiol 34: 1175-1179, 2013.

3. Bryan JY, Gao GY, Feng JF, Mao Q, Chen LG, Yang XF, Liu JF, Wang YH, Qiu BH and Huang XJ: Traumatic brain injury in China. Lancet Neurol 18: 286-295, 2019.

4. Chen J, Li M, Chen L, Chen W, Zhang C, Feng Y, Wang Y and Chen Q: The effect of controlled decompression for severe traumatic brain injury: A randomized, controlled trial. Front Neurol 11: 107, 2020.

5. Chen JH, Li PP, Yang LK, Chen L, Zhu J, Hu X and Wang YH: Value of ventricular intracranial pressure monitoring for traumatic bifrontal contusions. World Neurosurg 113: e690-e701, 2021.

6. Nichol A, French C, Little L, Haddad S, Presnell J, Araby I, Bailey M, Cooper DJ, Duranteau J, Huet O, et al: Erythropoietin in traumatic brain injury (EPO-TBI): A double-blind randomised controlled trial. Lancet 386: 2499-2506, 2015.

7. Hutchinson PJ, Kolaris AG, Timofeev IS, Corteau EA, Czosnyka M, Timothy J, Anderson I, Bulters DO, Belli A, Eynon CA, et al: Trial of decompressive craniectomy for traumatic intracranial hypertension. N Engl J Med 375: 119-130, 2016.

8. Cooper DJ, Nichol AD, Bailey M, Bernard S, Cameron PA, Pili-Floury S, Forbes A, Gantner D, Higgins AM, Huet O, et al: Effect of early sustained prophylactic hypothermia on neurologic outcomes among patients with severe traumatic brain injury: The POLAR randomized clinical trial. JAMA 320: 2211-2220, 2018.

9. Wright DW, Yeatts SD, Silbergleit R, Palesch YY, Hertzberg VS, et al: Effect of early sustained prophylactic hypothermia on neurologic outcomes among patients with severe traumatic brain injury: The POLAR randomized clinical trial. JAMA 320: 2211-2220, 2018.

10. Robertson CS, Hannay HJ, Yalam SD, Gopinath S, Goodman JC, Tilley BC: Epo Severe TBI Trial Investigators, Baldwin A, Rivera Lara L, Saeed-Crespo H, et al: Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: A randomized clinical trial. JAMA 312: 36-47, 2014.

11. Wang Y, Wang L, Hu T, Wang F, Han Z, Yin Z, Ge X, Xie K and Lei P: Hydrogen improves cell viability partly through inhibition of autophagy and activation of PI3K/Akt/GSK3β signal pathway in a microvascular endothelial cell model of traumatic brain injury. NeuroRes Rev 48: 457-460, 2020.

12. Li H, Lu C, Yao W, Xu L, Zhou J and Zheng B: Dexmedetomidine inhibits inflammatory response and autophagy through the circLrp1b/miR-27a-3p/Dram2 pathway in a rat model of traumatic brain injury. Aging (Albany NY) 12: 21687-21705, 2020.

13. Wang Y, Zhao M, Shang L, Zhang Y, Huang C, He Z, Luo M, Wu B, Song P, Wang M and Duan F: Homer1a protects against neuronal injury via PI3K/Akt/mTOR signaling pathway. Int J Neurosci 130: 621-630, 2020.

14. Ceccariglia S, Cargnoli A, Silini AR and Polaroni O: Autophagy: A potential key contributor to the therapeutic action of mesenchymal stem cells. Autophagy 16: 26-37, 2020.

15. Tang C, Shan Y, Hu Y, Fang Z, Tong Y, Chen M, Wei X, Fu X and Xu X: FG2F attenuates neural cell death via suppressing autophagy after rat mild traumatic brain injury. Stem Cells Int 2017: 2923182, 2017.

16. He G, Zhu Y, Wang D, Cao F, Fei M, Niu W, Zhou Y, Wang X, Li X and Zhou M: Basiclin protects mice brain from apoptosis in traumatic brain injury model through activation of autophagy. Front Neurosci 12: 1006, 2018.

17. Zhao M, Gao J, Cui C, Zhang Y, Jiang X and Cui J: Inhibition of PTEN ameliorates secondary hippocampal injury and cognitive deficits after intracerebral hemorrhage: Involvement of AKT/FoxO3a/ATG-mediated autophagy. Oxid Med Cell Longev 2021: 5472605, 2021.

18. Chen JH, Wu T, Xia WY, Shi ZH, Zhang CL, Chen L, Chen QX and Wang YH: An early neuroprotective effect of atorvastatin against subarachnoid hemorrhage. Neural Regen Res 15: 1947-1954, 2020.

19. Aron R, Pellegrini P, Green EW, Maddison DC, Opoku-Nsiah K, Oliveira AO, Wong JS, Daub AC, Giorgini F, Muchowski P and Finkbeiner S: Deubiquitinate Uspl2 functions noncatalytically to induce autophagy and confer neuroprotection in models of Huntington's disease. Nat Commun 9: 3191, 2018.

20. Yang T, Feng X, Zhao Y, Zhang H, Cui H, Cui W, Wei M, Yang H and Fan H: Dexmedetomidine enhances autophagy via α2-AR/AMPK/mTOR pathway to inhibit the activation of NLRP3 inflammasome and subsequently alleviates lipopolysaccharide-induced acute kidney injury. Front Pharmacol 11: 790, 2020.

21. Subramaniam B, Shankar P, Shafei S, Mueller A, O'Gara B, Banner-Goodspeed V, Gallagher J, Gasangwa D, Patmot X, Packiasabapathy S, et al: Effect of intravenous acetaminophen vs placebo combined with propofol or dexmedetomidine on postoperative delirium among older patients following cardiac surgery: The DEXACET randomized clinical trial. JAMA 321: 686-696, 2019.

22. Huang GR and Hao FG: Dexmedetomidine inhibits inflammation to alleviate early neuronal injury via TLR4/Nf-κB pathway in rats with traumatic brain injury. Crit Rev Eukaryot Gene Expr 31: 41-47, 2021.

23. Bilodeau V, Saavedra-Mitjans M, Frenette AJ, Burry L, Albert M, Amsler M, Barchi P, Bilodeau V, Janvier M, Carriere P, et al: Autophagy: A potential key contributor to the therapeutic action of mesenchymal stem cells. Autophagy 16: 26-37, 2020.

24. Ceccariglia S, Cargnoli A, Silini AR and Parolini O: Autophagy: A potential key contributor to the therapeutic action of mesenchymal stem cells. Autophagy 16: 26-37, 2020.

25. Shankar J and Vandorpe R: CT perfusion for confirmation of brain death. AJNR Am J Neuroradiol 34: 1175-1179, 2013.

26. Bryan JY, Gao GY, Feng JF, Mao Q, Chen LG, Yang XF, Liu JF, Wang YH, Qiu BH and Huang XJ: Traumatic brain injury in China. Lancet Neurol 18: 286-295, 2019.

27. Chen J, Li M, Chen L, Chen W, Zhang C, Feng Y, Wang Y and Chen Q: The effect of controlled decompression for severe traumatic brain injury: A randomized, controlled trial. Front Neurol 11: 107, 2020.

28. Chen JH, Li PP, Yang LK, Chen L, Zhu J, Hu X and Wang YH: Value of ventricular intracranial pressure monitoring for traumatic bifrontal contusions. World Neurosurg 113: e690-e701, 2018.

29. Nichol A, French C, Little L, Haddad S, Presnell J, Araby I, Bailey M, Cooper DJ, Duranteau J, Huet O, et al: Erythropoietin in traumatic brain injury (EPO-TBI): A double-blind randomised controlled trial. Lancet 386: 2499-2506, 2015.

30. Hutchinson PJ, Kolaris AG, Timofeev IS, Corteau EA, Czosnyka M, Timothy J, Anderson I, Bulters DO, Belli A, Eynon CA, et al: Trial of decompressive craniectomy for traumatic intracranial hypertension. N Engl J Med 375: 119-130, 2016.

31. Cooper DJ, Nichol AD, Bailey M, Bernard S, Cameron PA, Pili-Floury S, Forbes A, Gantner D, Higgins AM, Huet O, et al: Effect of early sustained prophylactic hypothermia on neurologic outcomes among patients with severe traumatic brain injury: The POLAR randomized clinical trial. JAMA 320: 2211-2220, 2018.

32. Wright DW, Yeatts SD, Silbergleit R, Palesch YY, Hertzberg VS, Frankel M, Goldstein FC, Caveney AF, Howlett-Smith H, Bengalink EM, et al: Very early administration of progesterone for acute traumatic brain injury. N Engl J Med 371: 2457-2466, 2014.
27. Dou R, Qian J, Wu W, Zhang Y, Yuan Y, Guo M, Wei R, Yang S, Jurczyszyn A, Janz S, et al: Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma. Cell Death Dis 12: 206, 2021.

28. Li J, Tian M, Hua T, Wang H, Yang M, Li W, Zhang X and Yuan H: Combination of autophagy and NFE2L2/NRF2 activation as a treatment approach for neuropathic pain. Autophagy: April 9, 2021 (Epub ahead of print).

29. He J, Yu T, Song Y and Yu Y: Netrin-1 alleviates subarachnoid haemorrhage-induced brain injury via the PPAR gamma/NF-kappaB signalling pathway. J Cell Mol Neurosci 13: 110, 2020.

30. Chen J, Zhang C, Yan T, Yang L, Wang Y, Shi Z, Li M and Chen Q: The potential value of targeting ferroptosis in early brain injury after acute CNS disease. Front Mol Neurosci 11: 551, 2020.

31. Chen J, Zhang C, Yan T, Yang L, Wang Y, Shi Z, Li M and Chen Q: Atorvastatin ameliorates early brain injury after subarachnoid hemorrhage via inhibition of pyroptosis and neuroinflammation. J Cell Physiol: Mar 3, 2021 (Epub ahead of print).

32. National Research Council (US) Institute for Laboratory Animal Research: Guide for the Care and Use of Laboratory Animals. National Academies Press (US), Washington, DC, 1996.

33. Flierl MA, Stahel PF, Beauchamp KM, Morgan SJ, Smith WR and Shoahmi E: Mouse closed head injury model induced by a weight-drop device. Nat Protoc 4: 1328-1337, 2009.

34. Tian J, Yang L, Wang P, Yang L and Fan Z: Exogenous CGRP regulates apoptosis and autophagy to alleviate traumatic brain injury through Akt/mTOR signalling pathway. Neurochem Res 45: 2926-2938, 2020.

35. Chen J, Xuan Y, Chen Y, Wu T, Chen L, Guan H, Yang S, He Z, He H and Liu Q: The nephroprotective effects and mechanisms of rehmapicrosin in H9c2 cells. Environ Toxicol 36: 1389-1401, 2021.

36. Cui G, Li Z, Yang L, Wang J, Li C, Ding H, Ye J and Xia Z: Dexmedetomidine reverses MTX-induced neurotoxicity and inflammation in hippocampal HT22 cell lines via NCOA4-mediated ferritinophagy. Aging (Albany NY) 13: 6182-6193, 2021.

37. Chen X, Chen D, Li Q, Wu S, Pan J, Liao Y, Zheng X and Zeng W: Dexmedetomidine alleviates hypoxia-induced synaptic loss and cognitive impairment via inhibition of microglial NOX2 activation in the hippocampus of neonatal rats. Oxid Med Cell Longev 2021: 6643171, 2021.

38. Mei B, Li J and Zuo Z: Dexmedetomidine attenuates sepsis-associated inflammation and encephalopathy via central α2A adrenoceptor. Brain Behav Immun 91: 296-314, 2021.

39. Yang YF, Wang H, Song N, Jiang YH, Zhang J, Meng XW, Feng XM, Liu H, Peng K and Ji FH: Dexmedetomidine attenuates ischemia/reperfusion-induced myocardial inflammation and apoptosis through inhibiting endoplasmic reticulum stress signaling. J Inflamm Res 14: 1271-1233, 2021.

40. Gao Y, Zhang Y, Dong Y, Wu X and Liu H: Dexmedetomidine mediates neuroglulin Up-regulation and alleviates the hypoxia/reoxygenation injury by inhibiting neuronal apoptosis in developing rats. Front Pharmacol 11: 555332, 2020.

41. Sun YB, Zhao H, Mu DL, Zhang W, Cui J, Wu L, Alam A, Wang DX and Ma D: Dexmedetomidine inhibits astrocyte pyroptosis and subsequently protects the brain in vitro and vivo models of sepsis. Cell Death Dis 10: 167, 2019.

42. Shen R, Pan D, Wang Z, Jin X, Li Z and Wang H: The effects of dexmedetomidine post-conditioning on cardiac and neurological outcomes after cardiac arrest and resuscitation in swine. Shock 55: 388-395, 2021.

43. Nixon RA: The role of autophagy in neurodegenerative disease. Nat Med 19: 983-997, 2013.

44. Zeng Z, Zhang Y, Jiang W, He L and Qu H: Modulation of autophagy in traumatic brain injury. J Cell Physiol 235: 1973-1985, 2020.

45. Xue H, Wu Z, Xu Y, Gao Q, Zhang Y, Li C and Zhao P: Dexmedetomidine post-conditioning ameliorates long-term neurological outcomes after neonatal hypoxic ischemia: The role of autophagy. Life Sci 270: 118980, 2021.

46. Wang M, Ke Y, Li Y, Shan Z, Mi W, Cao Y, Feng W and Zheng X: The nephroprotective effects and mechanisms of rehmapicrosin include ROS inhibition via an oestrogen-like pathway both in vivo and in vitro. Biomed Pharmacother 138: 111305, 2021.

47. Cui G, Li Z, Cao F, Li P, Jin M, Hou S, Yang X, Mu Y, Peng C, Shao H and Du Z: Activation of Nrfl2/HO-1 signaling pathway attenuates ROS-mediated autophagy induced by silica nanoparticles in H9c2 cells. Environ Toxicol 36: 1389-1401, 2021.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.